New tests for prostate cancer may be nearing the clinic.
Tuma
Rabiya S
RS
D058891:5-alpha Reductase Inhibitors; D000951:Antigens, Neoplasm / Q000652:urine*; D001378:Azasteroids / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000652:urine*; D001706:Biopsy; D002986:Clinical Trials as Topic; D004273:DNA, Neoplasm / Q000032:analysis; D003937:Diagnosis, Differential; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000652:urine*; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology / Q000517:prevention & control / Q000652:urine; D012333:RNA, Messenger / Q000652:urine; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D058891:5-alpha Reductase Inhibitors; D000951:Antigens, Neoplasm; D001378:Azasteroids; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; C515553:TMPRSS2-ERG fusion protein, human; C479341:prostate cancer antigen 3, human; D017430:Prostate-Specific Antigen; D000068538:Dutasteride